Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ayodhia Pitaloka Pasaribu has a total of 425 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Role of Thiamine in Pediatric CHD: Effects on LV Function and MMP-9/TIMP-1

    by Putri Amelia, Henry Salim Siregar, Tina Christina Tobing, Mulyadi M. Djer, Ayodhia Pitaloka Pasaribu, Oke Rina Ramayani, Mustafa Mahmud Amin, Muhammad Rusda, Dina Keumala Sari

    Congenital Heart Disease (CHD) represents the predominant form of congenital anomaly and occurs in approximately 0.8% of live births. Surgical correction is the definitive method used to treat CHD; however, postoperative complications can increase the risk of mortality and morbidity. Transcatheter closure has emerged as an alternative therapy for some CHD with left-to-right shunts, providing outcomes comparable with those of surgical correction. This narrative review was conducted to synthesize existing literature on the effect of thiamine supplementation in pediatric patients undergoing transcatheter closure for left-to-right shunt CHD. Thiamine deficiency in pediatric heart disease can weaken the heart by reducing its energy supply. Conversely, harmful changes to the heart’s structure are linked to a specific enzyme balance. Since evidence suggests thiamine can correct this imbalance, thiamine supplementation may represent a therapeutic strategy to improve heart structure and function after treatment. In individuals with systolic heart failure, supplementation with thiamine has been associated with an enhancement in Left Ventricular Ejection Fraction (LVEF). Thiamine acts directly on cardiomyocytes, enhancing energy production and improving cardiac function. Therefore, thiamine administration during transcatheter closure is expected to stabilize the Matrix Metalloproteinase- 9 (MMP-9) and Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) levels, which may enhance or improve left ventricular function and dimensions.

  • Open Access

    Predictive Value of CRIB II Score, Hematological Markers and Maternal-Fetal Risk Factors for Mortality in Neonatal Sepsis

    by Bugis Mardina Lubis, Cindy Clarissa Sirait, Ika Citra Dewi Tanjung, Arlinda Sari Wahyuni, Ayodhia Pitaloka Pasaribu

    Background: Neonatal sepsis is a leading cause of neonatal morbidity and mortality, particularly in low- and middle-income countries. Accurate early prediction of mortality is essential to improve clinical outcomes. The Clinical Risk Index for Babies II (CRIB II) and hematological indices such as the platelet-to-lymphocyte ratio (PLR) have emerged as potential prognostic tools, but their performance in septic neonates has not been fully established. Methods: A retrospective observational study was conducted on 80 neonates diagnosed with sepsis at a tertiary referral hospital. Demographic, maternal, and laboratory data—including CRIB II, neutrophil-to-lymphocyte ratio (NLR), PLR, mean platelet volume (MPV), and red-cell distribution width (RDW)—were analyzed. Receiver operating characteristic (ROC) curves were used to determine optimal cutoff values, and multivariate logistic regression identified independent predictors of mortality. Statistical significance was set at p < 0.05. Results: Among the 80 neonates, 40 (50%) did not survive. Non-survivors had significantly higher CRIB II scores (median 5.0 [1.0–13.0]) than survivors (2.0 [0–7.0]) (p < 0.001). PLR and MPV were also elevated in non-survivors (PLR: 88.5 vs. 51.8, p < 0.001; MPV: 10.5 vs. 9.5, p < 0.001). ROC analysis demonstrated strong predictive accuracy for mortality: CRIB II (AUC = 0.835; cutoff > 3.5; sensitivity 82.5%; specificity 78.0%) and PLR (AUC = 0.757; cutoff > 81.33; sensitivity 80.0%; specificity 70.0%). Multivariate analysis confirmed three independent predictors—PROM > 24 h (OR = 12.23; 95% CI: 2.05–73.11), PLR > 81.33 (OR = 91.02; 95% CI: 7.00–1184.29), and CRIB II > 3.5 (OR = 101.37; 95% CI: 4.50–2284.47). Conclusions: CRIB II and PLR are reliable, independent predictors of mortality in neonatal sepsis. Their integration with maternal factors such as prolonged rupture of membranes may improve early risk stratification and guide targeted interventions, particularly in resource-limited neonatal care settings.


  • Open Access

    Ivermecatin induces cytotoxic effects in SUP-B15 cell line

    by Olga Rasiyanti Siregar, Arlinda Sari Wahyuni, Ayodhia Pitaloka Pasaribu, Deri Edianto, I Dewa Gede Ugrasena, Rina Amelia, Inke Nadia Diniyanti Lubis, Muhammad Rusda

    Background. Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required. Ivermectin (IVM), widely used as an anthelmintic agent, has been reported to possess anticancer properties through various mechanisms. These properties suggest IVM as a potential alternative treatment for ALL. This study aims to evaluate the role of IVM in inducing cytotoxic effects in the ALL cell line SUP-B15. Methods. The ALL cell line SUP-B15 was examined following treatment with IVM at concentrations of 5, 10, and 20 μM. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cytotoxic effects of IVM, including measurements of optical density, cell inhibition, and cell viability. Results. IVM demonstrated inhibitory effects on SUP-B15 cells starting at a low dose of 5 μM. The half maximal inhibitory concentration (IC50) of IVM was 5 µM, showing an inhibitory effect of 54.18 ± 0.03% (95% confidence interval: 54.11-54.25%; p < 0.001). Treatment with 10 μM IVM demonstrated the most significant inhibitory effect (59.05 ± 0.1%) and the lowest cell viability (40.95 ± 0.01%). Conclusions. IVM holds potential as a promising alternative therapeutic agent for the treatment of ALL.

  • Open Access

    Current Profile of Vivax Malaria in Isolated Area of Kualuh Leidong

    by Ayodhia Pitaloka Pasaribu, Vincent Jimanto, Framita Ainur

    The Indonesian Ministry of Health targets to eliminate malaria by 2030. Vivax malaria, a challenging variant to eradicate, is prevalent in areas near elimination, including North Sumatra, which ranks fourth in malaria cases in Indonesia. Labura district, a part of North Sumatra, had a low-endemic status until 2020. However, an increase in cases occurred in 2021 within the Kualuh Leidong subdistrict, the primary contributor to Labura's malaria cases. This shifted the endemicity status from low to moderate. The objective of the study is to assess the malaria case profile in this region. A descriptive approach was used, employing a total sampling method at Tanjung Leidong Health Center between September 2022 and July 2023. This observational study identified 494 vivax malaria cases. Predominantly affecting males (60.9%), cases peaked in adults (>18 years) with 314 cases (63.6%). Microscopic examination was the leading diagnostic tool, used in 463 cases (93.7%). The health center primarily administered national regimen therapies dihydroartemisinin-piperaquine (DHP) + primaquine in 204 cases (62.4%), whereas others received alternate therapies. All patients recovered without referrals. Over 11 months, seven recurrence cases emerged, with five receiving quinine+primaquine. Vivax malaria cases in Kualuh Leidong have seen a significant increase compared to previous years. The attention and collaboration of all parties, both from the health center and the community, are necessary to achieve malaria elimination by 2030.

  • Open Access

    Ivermectin and dexamethasone combination induces apoptosis in SUP-B15 cell line

    by Olga R. Siregar, Arlinda S. Wahyuni, Ayodhia P. Pasaribu, Deri Edianto, I Dg. Ugrasena, Rina Amelia, Inke Nd. Lubis, Muhammad Rusda

    The development of glucocorticoid resistance has complicated the management of acute lymphoblastic leukemia (ALL), leading to increased mortality rates. Ivermectin, a low-cost and well-established anthelmintic, exhibits anticancer potential and may enhance glucocorticoid toxicity in ALL, offering a possible strategy to overcome resistance. The aim of this study was to evaluate the apoptotic effect of combining ivermectin with dexamethasone in ALL. ALL SUP-B15 cells were cultured under standard conditions before treatment with dexamethasone (200 nM) alone or combined with ivermectin (5, 10, and 20 µM), with an untreated group serving as the control. Cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay by measuring cell viability and inhibition. Apoptosis was evaluated through BAX, BCL-2, and CASP3 gene expression analysis using reverse transcription-polymerase chain reaction (RT-PCR). The findings revealed that the combination of ivermectin and dexamethasone was superior in the repression of ALL cell viability compared to control (p<0.001). The combination of dexamethasone 200 nM + ivermectin 20 μM demonstrated the most significant cell inhibition of 38.16±0.04% (p<0.001) and produced the lowest cell viability of 61.84±0.05% (p<0.001). Moreover, the combination of dexamethasone 200 nM + ivermectin 20 μM demonstrated superior upregulations of BAX (p<0.001) and CASP3 (p<0.001). In conclusion, the addition of ivermectin (5 µM) to dexamethasone regimen (200 nM) increases its cytotoxic and apoptotic activities against SUP-B15 cell line as observed by the CASP3 and BAX upregulation. Studies to confirm the enhanced anticancer activity by this combination by observing the protein levels and animal studies are warranted.

  • Open Access

    Factors associated with feeding problems in children with cerebral palsy: A cross-sectional study from Indonesia

    by Dwi S. Maulidia, Tiangsa Sembiring, Yazid Dimyati, Ika Cd. Tanjung, Arlinda S. Wahyuni, Winra Pratita, Halida R. Nasution, Olayan Alharbi, Ayodhia P. Pasaribu

    Children with cerebral palsy are at high risk for feeding difficulties and malnutrition due to motor impairments and associated conditions. The aim of this study was to evaluate the prevalence and types of feeding problems and their association with malnutrition in children with cerebral palsy. A cross-sectional study was conducted involving 54 children under five years old with cerebral palsy. Participants were classified into spastic cerebral palsy subtypes such as quadriplegic, hemiplegic, diplegic, or triplegic. Feeding problems were categorized as inappropriate feeding practices, reduced food intake, parental misperception, and food preferences using the Pediatric Symptom Checklist-17. Nutritional status was assessed using weight-for-age percentiles based on WHO growth charts. History of constipation and dysphagia were also recorded. Data analysis included Chi-square and Mann-Whitney U tests. Among the participants, 38.9% had hemiplegia, 33.3% diplegia, and 25.9% quadriplegia. Feeding problems were prevalent, with inappropriate feeding practices being the most common (70.4%). Malnutrition was identified in 59.3% of the children. However, no significant associations were observed between CP subtype or demographic variables and the types of feeding problems. Similarly, the type of feeding problem was not significantly associated with malnutrition. Constipation and dysphagia were reported in 31.5% and 37.0% of participants, respectively, and were significantly associated with nutritional status (p<0.001). In conclusion, feeding problems and malnutrition are common in children with cerebral palsy, with inappropriate feeding practices being the most prevalent issue. Although no significant associations were found between CP subtypes or the types of feeding problems and malnutrition, the findings emphasize the multifactorial nature of feeding challenges.


  • Open Access

    Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis

    by Ihsan Fadilah, Robert J. Commons, Nguyen Hoang Chau, Cindy S. Chu, Nicholas P. J. Day, Gavin C. K. W. Koh, Justin A. Green, Marcus Vg Lacerda, Alejandro Llanos-Cuentas, Erni J. Nelwan, et al.

    Background: The 8-aminoquinolines, primaquine and tafenoquine, are the only available drugs for the radical cure of Plasmodium vivax hypnozoites. Previous evidence suggests that there is dose-dependent 8-aminoquinoline induced methaemoglobinaemia and that higher methaemoglobin concentrations are associated with a lower risk of P. vivax recurrence. We undertook a systematic review and individual patient data meta-analysis to examine the utility of methaemoglobin as a population-level surrogate endpoint for 8-aminoquinoline antihypnozoite activity to prevent P. vivax recurrence. Methods and findings: We conducted a systematic search of Medline, Embase, Web of Science, and the Cochrane Library, from 1 January 2000 to 29 September 2022, inclusive, of prospective clinical efficacy studies of acute, uncomplicated P. vivax malaria mono-infections treated with radical curative doses of primaquine. The day 7 methaemoglobin concentration was the primary surrogate outcome of interest. The primary clinical outcome was the time to first P. vivax recurrence between day 7 and day 120 after enrolment. We used multivariable Cox proportional-hazards regression with site random-effects to characterise the time to first recurrence as a function of the day 7 methaemoglobin percentage (log base 2 transformed), adjusted for the partner schizonticidal drug, the primaquine regimen duration as a proxy for the total primaquine dose (mg base/kg), the daily primaquine dose (mg/kg), and other factors. The systematic review protocol was registered with PROSPERO (CRD42023345956). We identified 219 P. vivax efficacy studies, of which 8 provided relevant individual-level data from patients treated with primaquine; all were randomised, parallel arm clinical trials assessed as having low or moderate risk of bias. In the primary analysis data set, there were 1,747 patients with normal glucose-6-phosphate dehydrogenase (G6PD) activity enrolled from 24 study sites across 8 different countries (Indonesia, Brazil, Vietnam, Thailand, Peru, Colombia, Ethiopia, and India). We observed an increasing dose-response relationship between the daily weight-adjusted primaquine dose and day 7 methaemoglobin level. For a given primaquine dose regimen, an observed doubling in day 7 methaemoglobin percentage was associated with an estimated 30% reduction in the risk of P. vivax recurrence (adjusted hazard ratio = 0.70; 95% confidence interval [CI] [0.57, 0.86]; p = 0.0005). These pooled estimates were largely consistent across the study sites. Using day 7 methaemoglobin as a surrogate endpoint for recurrence would reduce required sample sizes by approximately 40%. Study limitations include the inability to distinguish between recrudescence, reinfection, and relapse in P. vivax recurrences. Conclusions: For a given primaquine regimen, higher methaemoglobin on day 7 was associated with a reduced risk of P. vivax recurrence. Under our proposed causal model, this justifies the use of methaemoglobin as a population-level surrogate endpoint for primaquine antihypnozoite activity in patients with P. vivax malaria who have normal G6PD activity.


  • Open Access

    Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

    by William H. K. Schilling, Mavuto Mukaka, James J. Callery, Martin J. Llewelyn, Cintia V. Cruz, Mehul Dhorda, Thatsanun Ngernseng, Naomi Waithira, Maneerat Ekkapongpisit, James A. Watson, et al.

    Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings: Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507. Interpretation: In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs. Trial registration: ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947.


  • Open Access

    Determinants of mortality in relationship between clinical and laboratory characteristics with the outcomes of children with diphtheria: A cross-sectional study at a national hospital of Sumatra region in 2020–2023

    by Shinta P. Dinanti, Oke R. Ramayani, Ayodhia P. Pasaribu

    In 2017, diphtheria outbreaks occurred in several provinces in Indonesia; however, the epidemiological data in the country is limited. The aim of this study was to determine the association between clinical findings and laboratory parameters associated with mortality of children with diphtheria. A retrospective cohort study was conducted at Haji Adam Malik General Hospital, Medan, Indonesia, covering diphtheria patients from January 2020 to December 2023. All patients aged 1–18 years clinically diagnosed with diphtheria were considered eligible. The associations between demographic characteristics, clinical features, immunization status, complications, and laboratory profiles with mortality were determined using Fisher's exact test, and the odds ratio (OR) with a 95% confidence interval (95%CI) was calculated. Our data indicated that the clinical characteristics of myocarditis (p=0.005) and airway obstruction (p=0.003) were associated with mortality. There was also a significant association between thrombocytopenia (p=0.020) and mortality in diphtheria patients. Patients with airway obstruction were 13 times more likely to have an increase in mortality compared to patients without airway obstruction. This study highlights that clinical and laboratory characteristics could be associated with in-hospital mortality of diphtheria cases, and therefore, pediatricians should be aware of the presence of those characteristics to prevent the mortality of the patients.


  • Open Access

    Determinants of COVID-19 severity and mortality in children: A retrospective and multicenter cohort study in Medan, Indonesia

    by Eka Airlangga, Arlinda S. Wahyuni, Jelita Siregar, Ririe F. Malisie, Bugis M. Lubis, Wiku B. Adisasmito, Muhammad Zarlis, Ayodhia P. Pasaribu

    This study investigated indicators of the severity and mortality of COVID-19 in children in Medan, Sumatera Utara Province, Indonesia. The aim of this study was to identify determinants of severity and outcome of children with COVID-19 as the lesson learned from the COVID-19 pandemic, particularly the limited health facilities in Indonesia. This retrospective cohort study was conducted in 2020, 2021, and 2022 at multiple centers. Inpatient and outpatient children confirmed to be SARS-CoV-2 positive were randomly recruited in the selected hospitals. Baseline data (demographic, clinical, laboratory and radiological data) were collected, and outcomes were classified as recovered/deceased (for the inpatient group) or returned to the hospital (for the outpatient group). Severity status was identified based on the Indonesia COVID-19 guidelines. The laboratory data were categorized according to international standards, and data were analyzed using univariate analyzes followed by multivariate logistic regression. A total of 303 inpatient and 114 outpatient children were included in the analysis. Out of the total inpatient cases, 11 patients died with 3.6 mortality rate. Our final multivariate indicated that the presence of shortness of breath (SOB), anemia, and abnormal C-reactive protein (CRP) levels were significantly associated with the severity or the presence of emergency signs, while the presence of SOB and comorbidities were significantly associated with mortality in inpatient children with COVID-19. The presence of fever, cough, SOB, muscle ache and diarrhea were the reasons why the children were returned to the hospital from self-isolation at home among outpatient COVID-19 cases; however, the cough was the only significant factor in the final multivariate mode. This study highlights important determinants of COVID-19 severity and mortality in children, which should be considered during clinical decision-making in low-resource settings of healthcare centers in Indonesia.